VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
This Quarter Return
+35.87%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$211M
AUM Growth
+$211M
(-13%)
Cap. Flow
-$85.7M
Cap. Flow
% of AUM
-40.6%
Top 10 Holdings %
Top 10 Hldgs %
8.5%
Holding
499
New
89
Increased
112
Reduced
218
Closed
57
Top Buys
| 1 |
Delek Logistics
DKL
|
$1.51M |
| 2 |
Western Midstream Partners
WES
|
$1.18M |
| 3 |
Viper Energy
VNOM
|
$953K |
| 4 |
Marathon Petroleum
MPC
|
$839K |
| 5 |
EPR Properties
EPR
|
$814K |
Top Sells
| 1 |
Barings BDC
BBDC
|
$2.75M |
| 2 |
Prospect Capital
PSEC
|
$2.59M |
| 3 |
WhiteHorse Finance
WHF
|
$2.34M |
| 4 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
$2.34M |
| 5 |
Nuveen Credit Strategies Income Fund
JQC
|
$2.27M |
Sector Composition
| 1 | Healthcare | 33.94% |
| 2 | Real Estate | 15.9% |
| 3 | Energy | 15.5% |
| 4 | Materials | 8.79% |
| 5 | Financials | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
Akebia Therapeutics
AKBA
$827M
| $425K | 0.2% |
31,293
-24,977
| -44% | -$339K |
|
177
Corbus Pharmaceuticals
CRBP
$119M
| $425K | 0.2% |
1,690
-688
| -29% | -$173K |
|
178
Main Street Capital
MAIN
$5.87B
| $423K | 0.2% |
13,585
-37,653
| -73% | -$1.17M |
|
179
AnaptysBio
ANAB
$630M
| $422K | 0.2% |
18,899
-3,956
| -17% | -$88.3K |
|
|
SYRS
180
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $422K | 0.2% |
+3,958
| New | +$422K |
|
181
Sixth Street Specialty
TSLX
$2.32B
| $421K | 0.2% |
25,549
-91,001
| -78% | -$1.5M |
|
|
KRTX
182
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $420K | 0.2% |
3,766
-1,750
| -32% | -$195K |
|
183
Vir Biotechnology
VIR
$765M
| $419K | 0.2% |
+10,226
| New | +$419K |
|
|
TBIO
184
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $419K | 0.2% |
23,395
-18,217
| -44% | -$326K |
|
185
Arcutis Biotherapeutics
ARQT
$1.91B
| $415K | 0.2% |
+13,718
| New | +$415K |
|
186
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $415K | 0.2% |
+16,274
| New | +$415K |
|
187
MEI Pharma
MEIP
$149M
| $414K | 0.2% |
+5,018
| New | +$414K |
|
188
Mersana Therapeutics
MRSN
$34.8M
| $411K | 0.19% |
+703
| New | +$411K |
|
189
Korro Bio
KRRO
$244M
| $409K | 0.19% |
+352
| New | +$409K |
|
190
Bain Capital Specialty
BCSF
$1.01B
| $408K | 0.19% |
36,795
-24,553
| -40% | -$272K |
|
|
IGMS
191
DELISTED
IGM Biosciences
IGMS
| $408K | 0.19% |
+5,592
| New | +$408K |
|
192
CEL-SCI Corp
CVM
$81.4M
| $405K | 0.19% |
904
-644
| -42% | -$289K |
|
193
Rocket Pharmaceuticals
RCKT
$358M
| $404K | 0.19% |
19,310
+2,895
| +18% | +$60.6K |
|
194
Xencor
XNCR
$594M
| $399K | 0.19% |
12,325
+2,692
| +28% | +$87.1K |
|
195
Axsome Therapeutics
AXSM
$6.09B
| $398K | 0.19% |
4,839
-2,849
| -37% | -$234K |
|
196
BridgeBio Pharma
BBIO
$9.91B
| $398K | 0.19% |
12,211
+2,351
| +24% | +$76.6K |
|
|
PHD
197
Pioneer Floating Rate Fund
PHD
$123M
| $398K | 0.19% |
41,811
-170,439
| -80% | -$1.62M |
|
|
TVRD
198
Tvardi Therapeutics, Inc. Common Stock
TVRD
$270M
| $398K | 0.19% |
647
+44
| +7% | +$27.1K |
|
199
TG Therapeutics
TGTX
$5.03B
| $397K | 0.19% |
20,382
-15,224
| -43% | -$297K |
|
|
AGEN
200
Agenus
AGEN
$136M
| $394K | 0.19% |
5,113
+343
| +7% | +$26.4K |
|